TScan Therapeutics (NASDAQ:TCRX) Posts Quarterly Earnings Results

TScan Therapeutics (NASDAQ:TCRX) issued its quarterly earnings results on Thursday. The company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.06), FiscalAI reports. TScan Therapeutics had a negative net margin of 1,655.35% and a negative return on equity of 108.72%. The firm had revenue of $0.59 million for the quarter, compared to analysts’ expectations of $0.46 million.

TScan Therapeutics Price Performance

NASDAQ TCRX traded down $0.01 on Thursday, hitting $0.17. The stock had a trading volume of 281,683 shares, compared to its average volume of 717,228. TScan Therapeutics has a 52-week low of $0.17 and a 52-week high of $1.47. The company has a debt-to-equity ratio of 0.31, a quick ratio of 3.37 and a current ratio of 3.37. The company has a market capitalization of $11.66 million, a price-to-earnings ratio of -0.19 and a beta of 1.21. The firm has a 50-day moving average of $0.27 and a 200-day moving average of $0.81.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on TCRX shares. Weiss Ratings lowered shares of TScan Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, September 8th. HC Wainwright lowered shares of TScan Therapeutics from a “buy” rating to a “neutral” rating and set a $1.00 price target on the stock. in a research report on Tuesday, September 8th. Wedbush downgraded shares of TScan Therapeutics from a “buy” rating to a “neutral” rating and set a $1.00 price objective for the company. in a report on Wednesday, September 2nd. Lifesci Capital downgraded TScan Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, September 2nd. Finally, Benchmark restated a “buy” rating on shares of TScan Therapeutics in a research report on Thursday, August 13th. Two investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $2.67.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc. is a clinical-stage biotechnology company developing T cell receptor-engineered T cell (TCR-T) therapies for cancer. Its approach involves genetically modifying a patient’s T cells to recognize specific cancer-related antigens, with the goal of directing the immune system to attack malignant cells. The company’s pipeline includes investigational therapies for hematologic malignancies and solid tumors. Its lead programs, TSC-100 and TSC-101, are designed to target the HA-1 antigen in patients with certain blood cancers following an allogeneic hematopoietic stem cell transplant.